Changes in corneal endothelial cell shape after treatment with one drop of ROCK inhibitor
Tóm tắt
We performed an investigation of the temporal impact on corneal endothelial cell (CEC) shape after ophthalmic instillation of one drop of the ROCK inhibitor, ripasudil. Subjects comprised 32 healthy adult volunteers, each of whom instilled ripasudil in the right eye. CEC shape [defined as CEC density (CECD), coefficient of variation (CV), and hexagonal cell rate (6A)], central corneal thickness (CCT), intraocular pressure (IOP), and conjunctival hyperemia were evaluated before instillation (baseline) and at 15 min, 1 h, 2 h, and 4–6 h after instillation by non-contact specular microscopy and slit-lamp microscopy. The incidence of pseudo gutta was also assessed. The CECD (cells/mm2) significantly decreased after instillation as follows: 2661 cells/mm2 at baseline, 2578 cells/mm2 at 15 min, 2527 cells/mm2 at 1 h, 2575 cells/mm2 at 2 h, and 2613 cells/mm2 at 4–6 h. After instillation, CV significantly increased and 6A significantly decreased. Pseudo gutta appeared in 18 subjects (56.3%) after instillation. There was no difference in CCT before and after instillation. IOP significantly decreased after instillation. The most severe conjunctival hyperemia was observed at 15 min after instillation, but had nearly disappeared within 2 h. Pseudo gutta appeared in more than half of the subjects, and the CEC shape changed upon instillation of one drop of ripasudil; however, it recovered at 4–6 h after instillation. Therefore, these changes would not greatly impact clinical treatment. Similar to the presence of conjunctival hyperemia, changes in CEC shape occur at early stages after instillation of ripasudil.
Tài liệu tham khảo
Honjo M, Tanihara H, Inatani M et al (2001) Effects of Rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci 42:137–144
Tanihara H, Inoue T, Yamamoto T et al (2016) One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. Acta Ophthalmol 94:e26–e34
Tanihara H, Inoue T, Yamamoto T et al (2015) Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost. A report of 2 randomized clinical trials. JAMA Ophthalmol 133:755–761
Inazaki H, Kobayashi S, Anzai Y et al (2017) One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy. Graefes Arch Clin Exp Ophthalmol 225:2009–2015
Tanihara H, Inoue T, Yamamoto T et al (2013) Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol 156:731–736
Terao E, Nakakura S, Fujisawa Y et al (2017) Time course of conjunctival hyperemia induced by a Rho-kinase inhibitor anti-glaucoma eye drop: ripasudil 0.4%. Curr Eye Res 42:738–742
Matsumura R, Inoue T, Matsumura A et al (2017) Efficacy of Ripasudil as a second-line medication in addition to a prostaglandin analog in patients with exfoliation glaucoma: a pilot study. Clin Drug Invest 37:535–539
Inoue K, Okayama R, Shiokawa M et al (2018) Efficacy and safety of adding ripasudil to existing treatment regimens for reducing intraocular pressure. Int Ophthalmol 38:93–98
Inoue K, Ishida K, Tomita G (2018) Effectiveness and safety of switching from prostaglandin analog monotherapy to prostaglandin/timolol fixed combination therapy or adding ripasudil. Jpn J Ophthalmol 62:508–516
Okumura N, Okazaki Y, Inoue R et al (2015) Rho-associated kinase inhibitor eye drop (Ripasudil) transiently alters the morphology of corneal endothelial cells. Invest Ophthalmol Vis Sci 56:7560–7567
Nakagawa H, Koizumi N, Okumura N et al (2015) Morphological changes of human corneal endothelial cells after Rho-associated kinase inhibitor eye drop (ripasudil) administration: a prospective open-label clinical study. PLoS ONE 10:e0136802
Japanese Ocular Allergology Society (2010) Guidelines for the clinical management of allergic conjunctival disease (2nd edition). Nippon Ganka Gakkai Zasshi 114:831–870 (in Japanese)
Nagayama K, Matsumoto T (2008) Contribution of actin filaments and microtubules to quasi-in situ tensile properties and internal force balance of cultured smooth muscle cells on a substrate. Am J Physiol Cell Physiol 295:C1569–C1578
Okumura N, Okazaki Y, Inoue R et al (2016) Effect of the Rho-associated kinase inhibitor eye drop (ripasudil) on corneal endothelial wound healing. Invest Ophthalmol Vis Sci 57:1284–1292
Wato E, Omichi K, Yoneyama S et al (2014) Safety evaluation of morphological changes in corneal endothelial cells induced by K-115 in cynomolgus monkeys. Fund Toxicol Sci 1:39–47
Tanihara H, Inoue T, Yamamoto T et al (2013) Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. JAMA Ophthalmol 131:1288–1295